Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you. Good morning and good ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...